Lv1
20 积分 2023-06-12 加入
Osimertinib plus datopotamab deruxtecan in patients with EGFR-mutated advanced NSCLC post-progression on first-line osimertinib: ORCHARD
27天前
已完结
Efficacy and Safety of Ultra-Low-Dose Immunotherapy in Relapsed Refractory Solid Tumors: Phase III Superiority Randomized Trial (DELII)
1个月前
已完结
Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody–drug conjugate, for patients with EGFR-mutated NSCLC: Pooled analysis of phase 1 and phase 2 trials
2个月前
已关闭
TBCRC 048 (Olaparib Expanded) Expansion Cohorts: Phase II Study of Olaparib Monotherapy for Patients With Metastatic Breast Cancer With Germline Mutations in PALB2 or Somatic Mutations in BRCA1 or BRCA2
2个月前
已关闭
Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial
2个月前
已完结
Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC — mechanisms and evolving treatment approaches
4个月前
已完结
RGI-2001 for the Prophylaxis of Acute Graft-Versus-Host Disease Following Allogeneic HCT
5个月前
已完结
Treatment of Relapsed and Refractory Follicular Lymphoma: Which Treatment for Which Patient for Which Line of Therapy?
5个月前
已关闭
Frontline treatment of follicular lymphoma: What will it take to change current practice?
5个月前
已完结
Clinical Characteristics, Treatment Responses and Outcomes of Light Chain Multiple Myeloma
5个月前
已完结
皖公网安备34019202002308
